LONDON and PHILADELPHIA – September 25, 2026 – Avacta Therapeutics (AIM: AVCT, the “Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces its pre|CISION® Platform has been honored by the Pharma Industry Awards UK 2026, winning the Research and Development Achievement Award.
The award recognizes that Avacta is pioneering the development of pre|CISION® to transform the landscape of targeted cancer therapies. It cites Avacta’s achievement of unprecedented milestones in research and development (R&D) over the last 12 months, demonstrating the platform’s potential to transform oncology treatment paradigms.
Christina Coughlin, CEO of Avacta, commented:
“We are delighted the pre|CISION® platform has received this honor as our scientists and clinicians have worked tirelessly to move the Next Gen pipeline forward and moved the first candidate, AVA6103, into the clinic with record speed. We are thrilled with the recognition of their efforts and the true innovation of the Next Gen pre|CISION® platform, which is designed to deliver highly potent anticancer payloads directly to the tumor, sparing the toxic effects in normal tissues.
“Our recent clinical data with AVA6103 point to the proof of this mechanism and we look forward to continued updates on the program and our full pipeline. We are grateful to the patients who are participating in the AVA6103 FOCUS-01 trial and for this recognition of our efforts from the Pharma Industry Awards UK 2026.”